LOGIN
ID
PW
MemberShip
2025-09-09 23:08
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Premium pricing for 11 linagliptin products ends on the 9th
by
Lee, Tak-Sun
Jun 4, 2025 06:19am
As one year has passed since the entry of generic versions of the DPP-4 inhibitor diabetes treatment Trajenta (linagliptin), the price ceiling of 11 products that received pricing premiums will be adjusted on the 9th. Three products that entered the market in March following the expiration of the first generic exclusivity period will also
Policy
Unveiling pledges of 2021 presidential election candidates
by
Lee, Jeong-Hwan
May 30, 2025 05:58am
Ahead of South Korea's 21st presidential election, two candidates from main political parties have unveiled their key election pledges in the areas of public healthcare¡¤biopharma¡¤national healthcare insurance. Lee Jae-myung (Candidate No.1), the presidential candidate of the Democratic Party of Korea, and Kim Moon-soo (Candidate No.2), t
Policy
Novo Nordisk applies for Wegovy¡¯s use in adolescents
by
Lee, Hye-Kyung
May 30, 2025 05:58am
With Novo Nordisk Korea applying for approval of Wegovy¡¯s use in adolescents aged 12 and older, the Ministry of Food and Drug Safety is planning strengthened measures to prevent its misuse and abuse. Wegovy is a glucagon-like peptide-1 (GLP-1) class obesity treatment that was launched in Korea in October last year. The drug has surpassed
Policy
Partial reimb for anticancer drug combos to be postponed
by
Lee, Tak-Sun
May 30, 2025 05:57am
The announcement of drugs eligible for partial reimbursement as anticancer drug combination therapy, which is currently in effect as of this month, is expected to be delayed until after June 1. Initially, the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee (CDDC) which convened on the 14th, planne
Policy
Lee pledges ¡®generic prescribing for essential medicines'
by
Lee, Jeong-Hwan
May 29, 2025 05:51am
The Democratic Party of Korea¡¯s presidential candidate Jae-Myung Lee (No. 1) pledged to introduce a limited implementation of the generic (ingredient-based) prescription system for essential medicines with unstable supply. The pledge also included plans to institutionalize telemedicine (non-face-to-face treatment) and establish a public
Policy
Lee ¡®promises support for essential medicine companies¡¯
by
Kang, Shin-Kook
May 29, 2025 05:50am
Jae-Myung Lee, presidential candidate for the Democratic Party of Korea, promised to support pharmaceutical companies producing essential medicines. On the 28th, Lee posted on his social media, ¡°The state will take responsibility for supporting the supply of essential medicines. Over the past 5 years, the supply of over 100 essential med
Policy
'Cabometyx' for ncRCC, failed to nego for expanded reimb
by
Lee, Tak-Sun
May 28, 2025 05:57am
The anticancer drug Cabometyx tab (cabozantinib, Ipsen Korea), a treatment of kidney cancer, did not pass the expanded reimbursement during negotiations with the National Health Insurance Service (NHIS). Cabometyx tab gatherered attention following reimbursement for the first-line treatment of patients with non-clear renal cell carcinoma
Policy
Expanded reimb for Jardiance's CKD indication imminent
by
Lee, Tak-Sun
May 27, 2025 06:19am
It is to be watched whether the SGLT-2 inhibitor Jardiance (empagliflozin, Boehringer Ingelheim) will be approved for expanded reimbursement to include chronic kidney disease (CKD) indication, in addition to diabetes and chronic heart failure indications. The evaluation by the Health Insurance Review & Assessment Service (HIRA) is expecte
Policy
Rinvoq reimbursed for active progressive psoriatic arthritis
by
Whang, byung-woo
May 27, 2025 06:18am
AbbVie Korea's Rinvoq has become the first oral JAK inhibitor to be covered by insurance for psoriatic arthritis in Korea. On the 26th, AbbVie Korea announced that Rinvoq (upadacitinib), a once-daily oral treatment and selective JAK inhibitor, will be reimbursed for the treatment of active and progressive psoriatic arthritis in adults
Policy
Moderate-risk trial granted for 'Amtagvi' for melanoma
by
Lee, Jeong-Hwan
May 26, 2025 05:56am
The government has approved a moderate-risk clinical study to treat refractory melanoma patients using the T-cell therapy, Amtagvi. The government also approved a high-risk clinical study that administer multi-virus antigen-specific immune T-cells to pediatric and adolescent patients with resistant¡¤refractory multi-virus infections who un
1
2
3
4
5
6
7
8
9
10
>